[go: up one dir, main page]

DK3199547T3 - Antistoflignende bindingsproteiner med dobbelt variabel region og overkrydsende orientering af bindingsregion - Google Patents

Antistoflignende bindingsproteiner med dobbelt variabel region og overkrydsende orientering af bindingsregion Download PDF

Info

Publication number
DK3199547T3
DK3199547T3 DK16205057.9T DK16205057T DK3199547T3 DK 3199547 T3 DK3199547 T3 DK 3199547T3 DK 16205057 T DK16205057 T DK 16205057T DK 3199547 T3 DK3199547 T3 DK 3199547T3
Authority
DK
Denmark
Prior art keywords
binding
region
country
orientation
cross
Prior art date
Application number
DK16205057.9T
Other languages
English (en)
Inventor
Nicolas Baurin
Christian Beil
Carsten Corvey
Christian Lange
Danxi Li
Vincent Mikol
Anke Steinmetz
Rao Ercole
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46927552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3199547(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK3199547T3 publication Critical patent/DK3199547T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK16205057.9T 2011-03-28 2012-03-28 Antistoflignende bindingsproteiner med dobbelt variabel region og overkrydsende orientering af bindingsregion DK3199547T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161468276P 2011-03-28 2011-03-28
FR1160311 2011-11-14
EP16169620.8A EP3112380A1 (en) 2011-03-28 2012-03-28 Dual variable region antibody-like binding proteins having cross-over binding region orientation

Publications (1)

Publication Number Publication Date
DK3199547T3 true DK3199547T3 (da) 2021-02-08

Family

ID=46927552

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12716818.5T DK2691416T3 (da) 2011-03-28 2012-03-28 Antistoflignende bindingsproteiner med dobbelt variabel region og overkrydsende orientering af bindingsregion
DK16205057.9T DK3199547T3 (da) 2011-03-28 2012-03-28 Antistoflignende bindingsproteiner med dobbelt variabel region og overkrydsende orientering af bindingsregion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12716818.5T DK2691416T3 (da) 2011-03-28 2012-03-28 Antistoflignende bindingsproteiner med dobbelt variabel region og overkrydsende orientering af bindingsregion

Country Status (32)

Country Link
US (7) US20120251541A1 (da)
EP (4) EP3199547B1 (da)
JP (6) JP6023172B2 (da)
KR (3) KR102607708B1 (da)
CN (3) CN110256569B (da)
AR (4) AR085726A1 (da)
AU (1) AU2012236603B2 (da)
BR (3) BR112013024758B1 (da)
CA (1) CA2831603C (da)
CL (1) CL2018001827A1 (da)
CO (1) CO6781527A2 (da)
CY (1) CY1118807T1 (da)
DK (2) DK2691416T3 (da)
ES (1) ES2588306T3 (da)
HR (1) HRP20161030T1 (da)
HU (1) HUE028230T2 (da)
IL (4) IL299392B1 (da)
LT (1) LT2691416T (da)
MA (1) MA35051B1 (da)
MX (1) MX338907B (da)
MY (1) MY164906A (da)
PH (1) PH12013502024A1 (da)
PL (2) PL2691416T3 (da)
PT (1) PT2691416T (da)
RS (2) RS55014B1 (da)
RU (1) RU2695880C2 (da)
SG (1) SG193916A1 (da)
SI (2) SI2691416T1 (da)
TW (6) TWI622597B (da)
UY (1) UY33983A (da)
WO (1) WO2012135345A1 (da)
ZA (1) ZA201307017B (da)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012145714A2 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
ES2798110T3 (es) 2012-02-13 2020-12-09 Agency Science Tech & Res Anticuerpos monoclonales humanos neutralizantes de IL-beta
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
FI3366705T3 (fi) 2012-09-12 2023-07-28 Genzyme Corp Muuttuneen glykosylaation ja vähentyneen efektoritoiminnan omaavia fc:n sisältäviä polypeptidejä
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
MX2015008446A (es) 2012-12-28 2016-10-26 Abbvie Inc Composiciones de proteinas de union multivalentes.
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
SI2943511T1 (sl) 2013-01-14 2020-01-31 Xencor, Inc. Novi heterodimerni proteini
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JP2016515093A (ja) * 2013-02-05 2016-05-26 サノフイ 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤
IL319584A (en) 2013-03-11 2025-05-01 Genzyme Corp Polypeptides with hyperglycosidic bonds
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
PT3406633T (pt) 2013-07-25 2022-05-04 Cytomx Therapeutics Inc Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos
CN104418947A (zh) * 2013-09-11 2015-03-18 香港大学 抗her2和抗-igf-ir的双特异性抗体及其用途
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN113388629A (zh) * 2014-02-07 2021-09-14 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
ES2940903T3 (es) 2014-03-19 2023-05-12 Genzyme Corp Glucomanipulación específica del sitio de restos orientadores
SG11201607983YA (en) 2014-03-28 2016-10-28 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
CN104974258B (zh) * 2014-04-01 2019-06-14 三生国健药业（上海）股份有限公司 重组抗hgf/dll4双特异性抗体、其制备方法和应用
US10647777B2 (en) 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
TWI745962B (zh) * 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
PT3170005T (pt) * 2014-07-18 2019-07-16 Sanofi Sa Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
CN107109456B (zh) 2014-09-03 2021-02-23 博灵格英格尔海姆国际股份公司 靶向IL-23A和TNF-α的化合物及其用途
CN113975406B (zh) 2014-10-09 2024-11-22 建新公司 糖工程化的抗体药物缀合物
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
AU2015353409B2 (en) 2014-11-26 2019-05-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
ES2824151T3 (es) * 2014-12-19 2021-05-11 Alkermes Inc Proteínas de fusión Fc monocatenarias
CA2969867C (en) * 2014-12-22 2022-01-25 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
CA2974453A1 (en) * 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
WO2016154290A1 (en) 2015-03-23 2016-09-29 Alexion Pharmaceuticals, Inc. Virus filtration
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
US10738095B2 (en) 2015-06-03 2020-08-11 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
EP4047020A1 (en) * 2015-06-15 2022-08-24 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format
EP3322436A4 (en) 2015-07-23 2019-03-27 Boehringer Ingelheim International GmbH OBJECTIVE COMPOUND AND USES THEREOF TO IL-23A AND B CELL ACTIVATING FACTOR (BAFF)
WO2017044811A1 (en) 2015-09-11 2017-03-16 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
WO2017059900A1 (en) * 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
WO2017062649A1 (en) 2015-10-07 2017-04-13 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN116675776A (zh) 2015-10-25 2023-09-01 赛诺菲 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
CN109293777A (zh) * 2015-11-13 2019-02-01 叶才果 双功能抗体及其用途
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DK3443006T5 (da) 2016-04-13 2024-09-16 Sanofi Sa Trispecifikke og/eller trivalente bindingsproteiner
BR112018070998A2 (pt) * 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
BR112018073945A2 (pt) 2016-05-27 2019-02-26 Alexion Pharmaceuticals, Inc. métodos para tratamento de miastenia grave generalizada refratária
MA45255A (fr) 2016-06-14 2019-04-17 Xencor Inc Anticorps inhibiteurs de points de contrôle bispécifiques
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
EP3504233B1 (en) 2016-08-26 2024-01-17 Sanofi Multispecific antibodies facilitating selective light chain pairing
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
PE20191033A1 (es) 2016-10-14 2019-08-05 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
WO2018075761A1 (en) 2016-10-19 2018-04-26 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5a in a sample
ES2848206T3 (es) 2016-10-19 2021-08-05 Alexion Pharma Inc Un método de cuantificar C5 sin unir en una muestra
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR20240049621A (ko) * 2017-02-17 2024-04-16 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
EP3615566B1 (en) * 2017-04-28 2023-12-20 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
JP2020519285A (ja) 2017-05-10 2020-07-02 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー 最適化された核酸抗体構築物
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
EP3645122A1 (en) 2017-06-30 2020-05-06 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
WO2019074973A2 (en) 2017-10-10 2019-04-18 Sanofi ANTI-CD38 ANTIBODIES AND METHODS OF USE
AU2018349093A1 (en) 2017-10-12 2020-05-28 Mcmaster University T cell-antigen coupler with Y182T mutation and methods and uses thereof
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR102722731B1 (ko) 2017-12-19 2024-10-25 젠코어 인코포레이티드 조작된 il-2 fc 융합 단백질
CA3087951A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
SG11202006410WA (en) 2018-01-12 2020-08-28 Genzyme Corp Methods for the quantitation of polypeptides
NZ767453A (en) 2018-01-26 2025-03-28 Genzyme Corp Fc variants with enhanced binding to fcrn and prolonged half-life
CA3093481A1 (en) * 2018-03-22 2019-09-26 Universitat Stuttgart Multivalent binding molecules
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
JP7612571B2 (ja) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
JP7462621B2 (ja) 2018-10-09 2024-04-05 サノフイ 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
US20220002393A1 (en) 2018-11-20 2022-01-06 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
EP3674316A1 (en) 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
BR112021012338A2 (pt) * 2018-12-24 2021-09-14 Sanofi Proteínas de ligação multiespecíficas com domínios fab mutantes
US11739160B2 (en) 2018-12-24 2023-08-29 Sanofi PseudoFab-based multispecific binding proteins
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CA3136821A1 (en) * 2019-04-09 2020-10-15 Sanofi Trispecific binding proteins, methods, and uses thereof
MX2021014931A (es) * 2019-06-07 2022-01-24 Amgen Inc Construcciones de union biespecificas con enlazadores selectivamente escindibles.
CN114466663A (zh) 2019-07-25 2022-05-10 建新公司 以FcRn拮抗剂治疗抗体介导的障碍的方法
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021026160A1 (en) 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
PE20220299A1 (es) * 2019-08-15 2022-03-07 Janssen Biotech Inc Materiales y metodos para fragmentos variables de cadena unica mejorados
US20210123926A1 (en) 2019-10-25 2021-04-29 Sanofi Methods for analyzing chain mispairing in multispecific binding proteins
BR112022009938A2 (pt) 2019-11-25 2022-09-13 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
US20230132241A1 (en) 2020-01-15 2023-04-27 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
IL295590A (en) 2020-02-28 2022-10-01 Genzyme Corp Optimized binding polypeptides to optimize drug conjugation
CN115605506A (zh) 2020-03-25 2023-01-13 伊莱利利公司（Us） 多特异性结合蛋白及其开发方法
CN115380048A (zh) * 2020-03-30 2022-11-22 赛诺菲 分裂ch2结构域
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2022040482A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022058539A1 (en) 2020-09-18 2022-03-24 Ichnos Sciences SA Cd47-cd38 bispecific antibodies
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
US20240190993A1 (en) 2021-04-14 2024-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
KR20240015093A (ko) 2021-05-27 2024-02-02 사노피 Fc 수용체에 대한 향상된 친화성 및 개선된 열 안정성을 갖는 Fc 변이체
EP4347660A4 (en) 2021-06-01 2025-06-04 Triumvira Immunologics USA, Inc. CLAUDIN-18.2 T-CELL ANTIGEN COUPLER AND USES THEREOF
WO2023274342A1 (zh) * 2021-06-30 2023-01-05 江苏恒瑞医药股份有限公司 特异性结合baff和il-12/23的抗原结合分子及用途
AU2022354068A1 (en) * 2021-09-29 2024-04-18 Modex Therapeutics, Inc. Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
JP2024540728A (ja) 2021-11-02 2024-11-01 ビステラ， インコーポレイテッド ＦＣＧａｍｍａｒおよびＣ１Ｑへの結合が無効化されたＦＣバリアント
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
MX2024010773A (es) * 2022-03-03 2024-09-10 Pfizer Anticuerpos multiespecificos y usos de estos.
US20240228650A9 (en) 2022-05-06 2024-07-11 Ichnos Sciences SA CD3/BCMA/CD38 Trispecific Antibodies
CN119213496A (zh) 2022-05-18 2024-12-27 赛诺菲 用于预测抗体的pk值的方法、系统和装置
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2023237690A2 (en) 2022-06-08 2023-12-14 Sanofi Methods for purification of multi-specific antibodies
TW202432574A (zh) 2022-10-25 2024-08-16 比利時商艾伯霖克斯公司 具有增強的效應子功能之糖基工程化Ｆｃ變體多肽
WO2024121311A1 (en) 2022-12-07 2024-06-13 Ichnos Sciences SA Cd47/cd38 bispecific antibodies and methods of use to treat leukemia
WO2024126833A1 (en) 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment
WO2025027003A1 (en) 2023-07-31 2025-02-06 Sanofi Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas
US20250154262A1 (en) 2023-10-25 2025-05-15 Ablynx N.V. Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1994013804A1 (en) * 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU6873396A (en) * 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
ES2225961T3 (es) 1996-04-04 2005-03-16 Unilever N.V. Proteina de union a antigeno multivalente y multiespecifica.
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
PL357939A1 (en) * 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
CN101684158A (zh) * 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2004232928A1 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2691434C (en) * 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
JP5485152B2 (ja) * 2007-08-15 2014-05-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 単一特異性および多特異性抗体ならびに使用方法
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2745460C (en) * 2008-12-19 2021-07-13 Macrogenics, Inc. Covalent diabodies and uses thereof
SMT202100250T1 (it) 2009-06-26 2021-07-12 Regeneron Pharma Anticorpi bispecifici facilmente isolati con formato di immunoglobulina nativo
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2012125775A1 (en) * 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
CA2974453A1 (en) * 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
BR112018070998A2 (pt) * 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
WO2019074973A2 (en) * 2017-10-10 2019-04-18 Sanofi ANTI-CD38 ANTIBODIES AND METHODS OF USE
JP7462621B2 (ja) * 2018-10-09 2024-04-05 サノフイ 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
EP3199547A1 (en) 2017-08-02
US20180155450A1 (en) 2018-06-07
ZA201307017B (en) 2014-05-28
BR122022004041B1 (pt) 2022-12-06
US9181349B2 (en) 2015-11-10
PL3199547T3 (pl) 2021-06-14
EP2691416B1 (en) 2016-05-18
TW201940510A (zh) 2019-10-16
JP7003101B2 (ja) 2022-02-04
TWI743461B (zh) 2021-10-21
PT2691416T (pt) 2016-08-26
IL228512B (en) 2018-10-31
JP6877371B2 (ja) 2021-05-26
IL299392A (en) 2023-02-01
IL261674A (en) 2018-10-31
BR122020011291B1 (pt) 2022-06-14
AR124511A2 (es) 2023-04-05
CN103562221B (zh) 2019-06-14
PH12013502024A1 (en) 2013-12-16
BR112013024758A2 (pt) 2018-07-10
MA35051B1 (fr) 2014-04-03
SI3199547T1 (sl) 2021-03-31
JP2018087211A (ja) 2018-06-07
MY164906A (en) 2018-02-15
CN110256569B (zh) 2025-01-07
EP2691416A1 (en) 2014-02-05
DK2691416T3 (da) 2016-09-05
IL261674B (en) 2020-06-30
KR102607708B1 (ko) 2023-11-30
AU2012236603B2 (en) 2015-06-18
US20160200811A1 (en) 2016-07-14
TWI803876B (zh) 2023-06-01
JP2014511684A (ja) 2014-05-19
AR124512A2 (es) 2023-04-05
RU2695880C2 (ru) 2019-07-29
SG193916A1 (en) 2013-11-29
AR124513A2 (es) 2023-04-05
RS61399B1 (sr) 2021-02-26
MX2013011176A (es) 2013-11-01
TWI588156B (zh) 2017-06-21
EP3805262A1 (en) 2021-04-14
CN103562221A (zh) 2014-02-05
MX338907B (es) 2016-05-05
KR101974901B1 (ko) 2019-05-08
AU2012236603A1 (en) 2013-04-18
TWI671315B (zh) 2019-09-11
US9221917B2 (en) 2015-12-29
CA2831603C (en) 2020-07-21
JP6023172B2 (ja) 2016-11-09
US20130345404A1 (en) 2013-12-26
KR20230166147A (ko) 2023-12-06
HUE028230T2 (en) 2016-12-28
RS55014B1 (sr) 2016-11-30
JP7603739B2 (ja) 2024-12-20
TW202212358A (zh) 2022-04-01
TWI622597B (zh) 2018-05-01
KR20210042183A (ko) 2021-04-16
JP2020058363A (ja) 2020-04-16
US20140056895A1 (en) 2014-02-27
CN110256568A (zh) 2019-09-20
SI2691416T1 (sl) 2016-10-28
IL299392B1 (en) 2025-06-01
PL2691416T3 (pl) 2016-11-30
NZ616174A (en) 2015-10-30
US20210189011A1 (en) 2021-06-24
EP3112380A1 (en) 2017-01-04
US20140011238A1 (en) 2014-01-09
CN110256569A (zh) 2019-09-20
CA2831603A1 (en) 2012-10-04
AR085726A1 (es) 2013-10-23
LT2691416T (lt) 2016-09-12
CY1118807T1 (el) 2018-01-10
EP3199547B1 (en) 2020-11-18
TW202317615A (zh) 2023-05-01
JP2022046668A (ja) 2022-03-23
TW201302786A (zh) 2013-01-16
BR112013024758B1 (pt) 2022-06-14
UY33983A (es) 2012-10-31
JP2023100752A (ja) 2023-07-19
IL261673B (en) 2020-06-30
KR20140019420A (ko) 2014-02-14
TW201808994A (zh) 2018-03-16
CO6781527A2 (es) 2013-10-31
IL228512A0 (en) 2013-12-31
JP2017038607A (ja) 2017-02-23
ES2588306T3 (es) 2016-11-02
TW201722988A (zh) 2017-07-01
RU2013147821A (ru) 2015-05-20
US20120251541A1 (en) 2012-10-04
TWI838039B (zh) 2024-04-01
IL261673A (en) 2018-10-31
CL2018001827A1 (es) 2018-08-31
HRP20161030T1 (hr) 2016-10-21
WO2012135345A1 (en) 2012-10-04
JP7273135B2 (ja) 2023-05-12
JP6490038B2 (ja) 2019-03-27

Similar Documents

Publication Publication Date Title
DK3199547T3 (da) Antistoflignende bindingsproteiner med dobbelt variabel region og overkrydsende orientering af bindingsregion
LTPA2019012I1 (lt) Plazmos kalikreiną surišantys baltymai
DK2547771T3 (da) Fremstilling af proteiner og polypeptider
DK2691443T3 (da) Konjugerede lipomerer og anvendelser af disse
DK2776466T3 (da) Albuminbindende antistoffer og bindingsfragmenter deraf
DK3333188T3 (da) Anti-NGF-antistoffer og deres anvendelse
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
DK3604339T3 (da) Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme
DK2771364T3 (da) Fremstilling af heterodimere proteiner
ME03075B (me) Prolaktin receptor vezujući proteini i njihova upotreba
DK2683406T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3418300T3 (da) Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
EP2528947A4 (en) CD127 BINDING PROTEINS
DK3199552T3 (da) Anti-ceacam5-antistoffer og anvendelser heraf
DK3662932T3 (da) Anti-cgrp-sammensætninger og anvendelse deraf
DK2742135T4 (da) Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf
DK2723771T3 (da) Serumalbuminbindende proteiner
PL2604625T3 (pl) Wytwarzanie cząsteczek wiążących
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
DK2606061T3 (da) Bindingsproteiner til hepcidin
DK2624866T3 (da) Tumorspecifikke antistoffer og anvendelser deraf
DK3434775T3 (da) Protein med nukleaseaktivitet, fusionsproteiner og anvendelser deraf
DK2882441T3 (da) Behandling af immunrelaterede og inflammatoriske sygdomme
DK2768321T3 (da) Fremgangsmåder og sammensætninger til induktion af mæthed